Development of AgNPs-tragacanth Conjugated Gel as a Novel Green Membrane in Electro-membrane Extraction: Tenofovir Disoproxil Fumarate Assay in Human Plasma Samples

Authors

  • Khalil Farhadi Department of Analytical Chemistry, Faculty of Chemistry, Urmia University, Urmia, Iran
  • Salahaddin Hajizadeh Department of Analytical Chemistry, Faculty of Chemistry, Urmia University, Urmia, Iran
Abstract:

AgNPs-Tragacanth conjugate gel as an eco friendly and low cost membrane was applied for the effective electromembrane extraction (EME) of Tenofovir disproxil fumarate, an important acidic and high polar (log p=1.25) antiviral drug, followed by HPLC-UV determination. The effect of various parameters on the extraction efficiency including the presence of AgNPs, tragacanth gum concentration, gel thickness, pH values of the donor and acceptor phases, applied voltage, extraction time and agitation rate were investigated and optimized. The best extraction efficiency was obtained with: 2.5% w/v of tragacanth gum, 4.0 mm gel thickness, donor phase pH = 7.0, acceptor phase pH = 8.0, applied voltage: 30 V, extraction time: 15 min and agitation rate: 500 rpm. During method validation under the optimized conditions good linearity dynamic range (LDR) between 10-750 ngmL-1 with coefficient of determination (R2) =0.999 was obtained. Limit of detection (LOD) and Limit of quantitation (LOQ) were estimated to be 5.55 ng mL-1 and 10 ng mL-1, respectively. According to the validation results, the RSD values for intra and inter-day precisions were in the range of 0.53 to 10.04% and the relative error (RE %) ranged between -2.31 to 8.20% Finally the applicability of this method in real samples was confirmed by an acceptable performance in extraction and determination of TDF in human plasma samples.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Tenofovir disoproxil fumarate.

Tenofovir disoproxil fumarate (tenofovir DF) is a bioavailable prodrug of tenofovir, a potent nucleotide analogue reverse-transcriptase inhibitor with activity against human immunodeficiency virus (HIV) and hepatitis B virus. It is administered as a single 300-mg tablet once daily. It was approved for the treatment of HIV infection on the basis of data from clinical trials demonstrating activit...

full text

Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate

Tenofovir disoproxil fumarate (TDF), the bisphosphonate ester prodrug of tenofovir (TFV), has poor bioavailability due to intestinal degradation and efflux transport. Reformulation using U.S. Food and Drug Administration-approved esterase and efflux inhibitors to increase oral bioavailability could provide lower dose alternatives and reduce costs for patients with HIV in resource-limited settin...

full text

The Epi-TAF for Tenofovir Disoproxil Fumarate?

Approximately 84% of human immunodeficiency virus (HIV)-infected US residents on antiretroviral therapy currently receive some form of tenofovir disoproxil fumarate (TDF) as part of their HIV treatment regimen. The TDF analogue tenofovir alafenamide (TAF) has demonstrated equal efficacy but with decreased renal injury and bone mineral density loss compared with TDF. We examine how much more soc...

full text

A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate

This Phase 1, randomized, two-site (United States), double-blind, placebo-controlled study enrolled 18 sexually abstinent men and women. All received a single 300-mg dose of oral tenofovir disoproxil fumarate (TDF) and were then randomized 2:1 to receive single and then seven daily rectal exposures of vaginally-formulated tenofovir (TFV) 1% gel or a hydroxyethyl cellulose (HEC) placebo gel. Blo...

full text

A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.

INTRODUCTION More than a million people acquire HIV infection annually. Pre-exposure prophylaxis (PrEP) using antiretrovirals is currently being investigated for HIV prevention. Oral and topical formulations of tenofovir have undergone preclinical and clinical testing to assess acceptability, safety and effectiveness in preventing HIV infection. AREAS COVERED The tenofovir drug development pa...

full text

Development of Membrane Bioreactor to Membrane Electro-bioreactor for Advanced Treatment of Wastewater

Limited available water resources have rendered wastewater reuse an important issue to specialists in most developed countries, today. The current study works on membrane filtration for treatment of industrial wastewater. By comparing the two methods of membrane bioreactor (MBR) and hybrid membrane electro bioreactor (MEBR) processes, it finds that earlier fouling in the membrane occurs in the ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 7  issue 4

pages  415- 429

publication date 2020-11-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023